Full history for every metric is available with a Kvantra account
Idogen AB (publ) (IDOGEN.ST)
Key financial summary
Financials in SEK| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | SEK m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | SEK m | -48 | -44 | |||||
| Net profit | SEK m | -21 | -28 | -33 | -27 | -39 | -48 | -44 |
| EPS reported | SEK | -0.76 | -7.81 | |||||
| Operating cashflow per share | SEK | -0.81 | -0.81 | |||||
| Capex per share | SEK | 0.03 | 0.03 | |||||
| FCF per share | SEK | -0.83 | -0.83 | |||||
| Free cash flow | SEK m | -52 | -42 | |||||
| Net debt | SEK m | -5 | -3 | |||||
| Book value equity | SEK m | 4 | 2 | |||||
| Book value per share | SEK | 0.06 | 2.12 | |||||
| Number of shares | m | 62.73 | 0.96 | |||||
| DPS (TTM paid) | SEK | 0.00 | 0.00 |
Financial summary
Financials in SEK| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 3.04 | 6.29 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.21 | -0.30 | |||||
| EV/EBITDA LTM | x | -0.12 | -0.23 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -433.69% | -629.84% | |||||
| FCF Yield | % | -476.82% | -328.67% | |||||
| Quality | ||||||||
| ROE | % | -1318.1% | -652.21% | |||||
| ROIC | % | -1328.1% | -1328.1% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.11 | 0.11 | |||||
| EBIT/Net interest | x | -47,972.00 | -47,972.00 | |||||
| Net debt/market cap | % | -48.32% | -23.25% | |||||
| Net debt/Equity | x | -1.47 | -1.46 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Idogen AB (publ) is a Swedish biotechnology company specializing in the development of tolerogenic cell therapies. These innovative treatments are engineered to prevent a patient's immune system from attacking crucial elements, including biological agents, transplanted organs, and the body's own cells or tissues. The company's most advanced product in development is IDO 8, designed for individuals with severe haemophilia A who have developed neutralizing antibodies against their vital coagulation factor VIII treatment. Idogen is also developing IDO T, a tolerogenic cell therapy intended to prevent organ transplant rejection, primarily for kidney transplants, and IDO AID, aimed at treating autoimmune diseases. Established in 2008, the company is headquartered in Lund, Sweden.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Idogen AB (publ) (IDOGEN.ST)
Idogen AB (publ) is a Swedish biotechnology company specializing in the development of tolerogenic cell therapies. These innovative treatments are engineered to prevent a patient's immune system from attacking crucial elements, including biological agents, transplanted organs, and the body's own cells or tissues. The company's most advanced product in development is IDO 8, designed for individuals with severe haemophilia A who have developed neutralizing antibodies against their vital coagulation factor VIII treatment. Idogen is also developing IDO T, a tolerogenic cell therapy intended to prevent organ transplant rejection, primarily for kidney transplants, and IDO AID, aimed at treating autoimmune diseases. Established in 2008, the company is headquartered in Lund, Sweden.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free